Delivery Order SPE2DB25D3404-SPE2DB25FUNCQ
- Not listed
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $10,172.74 for Shingrix vial kits on April 24, 2025, with an ultimate completion date of April 25, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999. The place of performance is AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Shingrix vial kits with a ceiling value of $1,139.18. This firm fixed-price delivery order, which is not set-aside, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, a $999.99 billion vehicle that extends through December 2026. The performance location is AmerisourceBergen's corporate...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Shingrix vial kits valued at $8,769.12, with an ultimate completion date of August 15, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which is valued at $999,999,999.00 and extends through December 2026. The place of performance is AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $3,417.54 to AmerisourceBergen Drug Corp for Shingrix vial kits on July 28, 2025, with completion expected by July 29, 2025. The contract is a firm fixed-price delivery order with no set-aside designation, indicating competitive award. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor and will perform the work at its corporate office location. Shingrix is a recombinant zoster vaccine used...
- The Defense Logistics Agency awarded a delivery order valued at $2,278.36 to AmerisourceBergen Drug Corp for Shingrix vial kits on July 16, 2025, with completion targeted for July 17, 2025. This competitively awarded, firm fixed price delivery order represents a small-value pharmaceutical procurement executed through AmerisourceBergen's existing contract vehicle with DLA. The work will be performed at the contractor's corporate office in Conshohocken, Pennsylvania. Shingrix is a recombinant...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for Shingrix vial kits valued at $1,139.18, with an ultimate completion date of August 25, 2025. This competitive, firm fixed price delivery order was issued on August 22, 2025, with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal medical procurement needs across the Department of Defense and other...
- The Defense Logistics Agency awarded a $15,032.22 delivery order to AmerisourceBergen Drug Corp for Shingrix vial kits, with an ultimate completion date of April 25, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and extending through December 2026. The place of performance is listed as Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a delivery order valued at $1,139.18 to AmerisourceBergen Drug Corp for Shingrix vial kits on June 2, 2025, with an ultimate completion date of June 3, 2025. This firm fixed-price contract, issued without a set-aside designation, represents a competitive award to the prime contractor for vaccine supply. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. As a child order under a larger contract vehicle, this...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Shingrix vial kits valued at $1,139.18, with an ultimate completion date of August 27, 2025. This non-set-aside, firm fixed price delivery order represents a competitively awarded procurement to supply vaccines supporting federal medical supply chain requirements. The contract is a child award under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated...
- The Defense Logistics Agency awarded a delivery order valued at $1,139.18 to AmerisourceBergen Drug Corp for Shingrix vial kits on August 4, 2025, with completion scheduled for August 5, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The place of performance is AmerisourceBergen's...
- SPE2DB25D3404Indefinite Delivery Contract
- SPE2DB25D3404-SPE2DB25FUNCQDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on April 24, 2025, for the supply of Shingrix vial kits, with a ceiling value of $1,544.06. This firm fixed-price delivery order is set to be completed by April 25, 2025, and represents a non-competitive continuation of AmerisourceBergen's substantial federal pharmaceutical supply relationship. The award is issued under a child contract vehicle, leveraging AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a primary pharmaceutical distributor serving federal military and veteran healthcare systems. The company's DLA Troop Support Medical contract encompasses a comprehensive portfolio of pharmaceutical products and medical supplies, including specialty medications, vaccines, and related medical commodities. Shingrix is a recombinant zoster vaccine used for the prevention of herpes zoster in older adults and certain immunocompromised populations, making it a critical component of military healthcare immunization programs. This delivery order exemplifies AmerisourceBergen's ongoing role as a key federal medical supply vendor, supporting the healthcare requirements of the Defense Health Agency and broader Department of Defense medical operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.5k | 4/24/25 |